Belite Bio (BLTE) Free Cash Flow (2024 - 2025)
Belite Bio's (BLTE) quarterly Free Cash Flow came in at -$10.4 million in Q4 2025, down 114.88% year-on-year from $69.8 million in Q4 2024, and down 114.88% quarter-over-quarter from -$4.8 million in Q4 2024.
Belite Bio (BLTE) Free Cash Flow (2024 - 2025) Analysis & Trends
Belite Bio's Free Cash Flow history runs 2 years deep, the most recent figure standing at -$10.4 million for Q4 2025.
- On a quarterly basis, Free Cash Flow fell 114.88% year-over-year to -$10.4 million in Q4 2025; TTM through Mar 2026 was -$10.4 million, a 114.88% decrease from a year earlier, with the FY2025 full-year figure at -$37.1 million, down 26.27% from the prior year.
- Free Cash Flow slipped to -$10.4 million in Q4 2025 per BLTE's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.8 million in Q4 2024 and bottomed at -$10.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 48.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.39 Mn |
| Dec 31, 2025 | -10.39 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Dec 31, 2024 | -4.83 Mn |